What the current evidence shows
Lean Rx, Inc. is the current platform operator. SkinnyRx's current terms identify Lean Rx, Inc. as the owner and operator, state that it is not a healthcare provider, and publish 2108 N Street, Suite N, Sacramento, California 95816 as the contact address. FDA's warning letter uses the same entity, trade name, address, and support email.
The current privacy policy names AyaRx as the telemedicine partner. Lean Rx facilitates access and platform services, while independent clinicians make medical decisions. The terms also explain that branded pathways may route medication billing and fulfillment to a third-party pharmacy or manufacturer-affiliated program.
Product pages identify Sajad Zalzala, MD as medical director. The federal NPPES registry lists Sajad Zalzala, MD under an active family-medicine NPI and multiple state license entries. That verifies the clinician identity, but not that he reviews every SkinnyRx patient. The app page spells the first name Sahad, creating an avoidable identity conflict.
The app page includes a Dr. Jess Mateus chat mockup, but no public roster, biography, NPI, or state-license table ties that name to prospective SkinnyRx care. The review therefore does not present the mockup as proof of an available treating clinician.
The current storefront presents four active compounded products: semaglutide injection, semaglutide sublingual tablets, tirzepatide injection, and tirzepatide sublingual tablets. The injection pages advertise weekly dosing and optional microdosing. The tablet pages describe once-daily use under the tongue.
The two semaglutide pages publish only a first-month promotion: $99 for injection and $149 for tablets on the pages reviewed. They do not state the ongoing renewal rate, plan commitment, strength, concentration, quantity, or final checkout total. Those amounts are kept as first-month prices and are not converted into ongoing monthly averages.
The tirzepatide injection page publishes $99 for the first month. The twelve-month option then charges $225 per month, producing a $2,574 total and $214.50 effective rate. The six-month option totals $1,349 or $224.83 per month, and the four-month option totals $966 or $241.50 per month.
The injection month-to-month option is $99 for the first month and $299 per month after that. The compact $245 average uses the ongoing $299 month-to-month rate rather than treating the temporary $99 promotion as the standard monthly plan price. It is the unweighted mean of $214.50, $224.83, $241.50, and $299.
The tirzepatide tablet page publishes $199 for the first month. The twelve-month option totals $2,674 or $222.83 per month, the six-month option totals $1,449 or $241.50 per month, and the three-month option totals $777 or $259 per month. The ongoing month-to-month renewal is $299, producing a compact four-plan average of about $256.
The tablet page's comparison block says the SkinnyRx figure reflects the twelve-month plan but displays $241.50 per month. That amount is the six-month effective rate, not the twelve-month rate of $222.83. This is a material price-copy error because it appears in a comparison intended to summarize cost.
Both tirzepatide pages say cancel anytime and show a 90-day money-back badge. The detailed terms are narrower. Subscriptions must be canceled at least five days before renewal, bundled subscriptions and partially used periods are non-refundable, and discounts tied to a promotional or committed term may be reversed or proportionally adjusted.
The guarantee is not an unconditional satisfaction refund. Eligibility requires ninety consecutive paid days, at least one weight log and one medication-dose log in the app every calendar week, an end weight equal to or above the starting weight, an active prescription, no prior refund or chargeback, and a claim within fourteen days after the guarantee period.
SkinnyRx's intake first asks about goals and health history. Product pages say a licensed clinician may review the submission within twenty-four hours and may require a short video visit depending on state and patient needs. A prescription is not guaranteed. Approved medication is then processed, with tracking described as arriving within two business days.
The charging sequence is not described consistently. Shop pages say the customer picks a plan and checks out before intake but is charged only once prescribed. Product FAQs say payment is processed after the prequalification intake and a disqualified customer receives a refund within twenty-four to forty-eight hours. The controlling sequence should be confirmed before entering payment information.
SkinnyRx says its providers are U.S.-based, licensed, and board-certified, but does not publish the assigned clinician or a state-by-state roster. Terms exclude certain compounded offerings in Alabama, Louisiana, and Mississippi. Broad platform marketing should not be read as proof that every product and formulation is available in every other state.
No dispensing pharmacy is named on the reviewed pages. SkinnyRx describes partner pharmacies as state-licensed 503A facilities and displays quality-testing claims, but provides no pharmacy name, license, laboratory, certificate, lot number, or test date that a prospective patient can verify before intake.
Injection pages describe potency, sterility, pH, and endotoxin checks. The semaglutide and tirzepatide tablet pages reuse the same sterility, pH, injection-irritation, and endotoxin sections even though the marketed products are sublingual tablets. They also reuse member outcomes described as coming from GLP-1 injections. Those sections do not establish product-specific evidence for the tablets.
FDA states that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. A state-licensed pharmacy or a displayed testing badge is not the same as FDA approval of the finished product. Patient-specific formulation, source ingredients, pharmacy oversight, and legal compounding basis matter.
FDA sent warning letter 717989 to Lean Rx, Inc. doing business as SkinnyRx after reviewing earlier website content. FDA cited label imagery that suggested SkinnyRx was the compounder and claims implying compounded semaglutide and tirzepatide were FDA-approved or otherwise evaluated. FDA requested corrective action and a response within fifteen working days.
Current SkinnyRx pages now state that compounded drugs are not FDA approved and that actual packaging may differ. Those changes are relevant, but they do not establish how FDA assessed the response. No public FDA close-out letter for warning letter 717989 was found during this review, so the draft describes the warning and current disclosures without declaring the matter closed or escalated.
The current contact page publishes support@skinnyrx.com, 1-888-979-9580, and support hours of Monday through Friday from 9 a.m. to 6 p.m. Eastern, with Saturday and Sunday closed. The same page later advertises 24/7 access to medical providers and community support, while product pages promise unlimited access. No response-time or urgent clinical escalation standard is public.
Shipping language also varies. Product pages advertise free overnight shipping, the app page says temperature-controlled medication arrives overnight, FAQs say tracking arrives within two business days, and a shop comparison says free two-to-three-day delivery. No universal carrier, cold-chain, temperature-excursion, lost-package, or replacement policy is published.
The app page markets care from $49 per month, prescription GLP-1 access, dose reminders, weight tracking, meal planning, messaging, and automatic refills. It does not establish that medication is included at $49. Current Wegovy pill and Foundayo pill product pages are marked unavailable, so those products remain outside the active comparison cards.
The current privacy policy describes collection of health information, app-entered weight and dose data, biometric information, session replay, precise or non-precise location, and targeted advertising data. It says some identifiers, demographic data, and internet activity may be sold or shared for advertising under applicable state-law definitions, while guarantee log data is reserved for guarantee administration except for legal, fraud, or dispute needs.
The public site displays a LegitScript verification link, but the checker presented a reCAPTCHA and did not expose a readable current result in this research session. The review therefore records the link without independently asserting a specific current certification status.
SkinnyRx can be easier to navigate than a clinic that hides every price, but the useful facts are spread across product, shop, app, contact, terms, and privacy pages. A prospective patient should save the exact checkout, ask for the pharmacy and label details, and reconcile renewal, cancellation, refund, guarantee, and shipping terms before committing.
- Current terms identify Lean Rx, Inc. as the SkinnyRx operator, and the privacy policy names AyaRx as the telemedicine partner.
- The four active products are compounded semaglutide and tirzepatide by injection or sublingual tablet; Wegovy pill and Foundayo pill are marked unavailable.
- Only the two tirzepatide routes publish enough comparable plan terms for a compact monthly average.
- The tirzepatide tablet comparison calls $241.50 the twelve-month price even though that number is the six-month effective rate.
- The public semaglutide pages show first-month promotions but not the ongoing renewal prices.
- No current page names the dispensing pharmacy or publishes exact strengths, concentrations, quantities, or linked lot certificates.
- The sublingual product pages reuse injection-specific member outcomes and sterility, pH, and endotoxin copy.
- FDA warning letter 717989 directly addressed Lean Rx dba SkinnyRx and cited false or misleading compounded-drug labeling and promotion.
- The contact page lists weekday-only support hours, while other pages advertise 24/7 access.
- The 90-day guarantee requires continuous payment, weekly app logging, no recorded weight loss, and a tightly timed claim.
- The privacy policy names health data, weight and dose logs, session replay, targeted advertising, and state-law sale or sharing of some data categories.